Ivim Health offers virtual consultations with licensed providers who specialize in personalized GLP-1 therapy, making expert care accessible regardless of your location
Compound Information Single-molecule triple incretin receptor agonist (GLP-1 / GIP / glucagon)
4144 This activation enhances the activity of POMC neurons, which induce satiety, while suppressing NPY neurons that drive hunger
If approved by the FDA, orforglipron will be the first oral GLP-1 medication for weight loss
TRIUMPH-4 represents Eli Lilly's first successful Phase 3 trial for Retatrutide, moving beyond the promising Phase 2 results from 2023 that showed 24% weight loss
These medications are typically administered via injection, although oral forms, like Rybelsus (semaglutide), are also available